Continued anifrolumab treatment studied for lupus and related diseases

NCT ID NCT07691970

Not yet recruiting Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study offers continued access to anifrolumab (Saphnelo) for people with systemic lupus erythematosus, systemic sclerosis, or myopathies who completed a prior anifrolumab trial and are still benefiting from the drug. Participants receive the same treatment as before, while researchers monitor long-term safety and side effects. The goal is to gather more information on the drug's safety over extended use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anifrolumab (Saphnelo)
What this could lead to: If successful, this study could show that long-term anifrolumab use is safe and effective for managing autoimmune diseases like lupus.
What could go wrong: This is an open-label rollover study, not a placebo-controlled trial, so results may be less definitive. Side effects remain possible with continued treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous lupus erythematosus myopathy systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC SCLEROSIS CUTANEOUS LUPUS E MYOPATHIES SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site

Los Angeles, California, 90045, United States
Research Site

Fort Lauderdale, Florida, 33309, United States
Research Site

Chicago, Illinois, 60611, United States
Research Site

Ann Arbor, Michigan, 48109, United States
Research Site

New York, New York, 10029, United States
Research Site

Charleston, South Carolina, 29425, United States
Research Site

Graz, 8010, Austria
Research Site

Graz, 8036, Austria
Research Site

Ghent, 9000, Belgium
Research Site

Salvador, 40150-150, Brazil
Research Site

Sofia, 1618, Bulgaria
Research Site

Bordeaux, 33076, France
Research Site

Strasbourg, 67200, France
Research Site

Toulouse, 31300, France
Research Site

Chaïdári, 124 62, Greece
Research Site

Kolkata, 700020, India
Research Site

Haifa, 31048, Israel
Research Site

Milan, 20122, Italy
Research Site

Sapporo, 060-8648, Japan
Research Site

Iloilo City, 5000, Philippines
Research Site

Lipa City, 4217, Philippines
Research Site

Bydgoszcz, 85-168, Poland
Research Site

Kielce, 25-316, Poland
Research Site

Krakow, 30-040, Poland
Research Site

Iași, 700661, Romania
Research Site

Kragujevac, 34000, Serbia
Research Site

Piešťany, 92101, Slovakia
Research Site

Seoul, 6591, South Korea
Research Site

Barcelona, 8041, Spain
Research Site

Granada, 18014, Spain
Research Site

Madrid, 28034, Spain
Research Site

Madrid, 28041, Spain
Research Site

Valencia, 46014, Spain
Research Site

Kaohsiung City, 83301, Taiwan
Research Site

Taichung, 404327, Taiwan
Research Site

Bangkok, 10700, Thailand
Research Site

Khon Kaen, 40002, Thailand
Research Site

Fatih-Istanbul, 34098, Turkey (Türkiye)
Research Site

London, SE5 9RS, United Kingdom
Research Site

Newcastle upon Tyne, NE7 7DN, United Kingdom
Research Site

Sheffield, S10 2JF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.